AX200: Development discontinued

In its 4Q11 earnings, Sygnis said it would evaluate potential M&A options and financing opportunities after discontinuing development of AX200 to treat stroke. Sygnis said an analysis of data from the double-blind, European Phase II AXIS 2 trial of AX200 showed "no hints of efficacy." In December, Sygnis reported top-line data from the trial showing that AX200 missed the primary endpoint of significantly improving mean modified Rankin Scale (mRS) scores vs. placebo. AX200 also missed the secondary endpoint of significantly improving mean National Institutes of Health Stroke Scale (NIHSS) scores vs. placebo. The trial enrolled 328 patients who had an acute ischemic stroke (see BioCentury, Dec. 19, 2011). ...